Aflibercept 100mg
| Product Overview | |
| Generic Name | Aflibercept 100mg |
| Brand Name(s) | EYLEA®, Zaltrap |
| Form | Single-dose vials for intravenous or intravitreal use |
| Strength | 100 mg/4 mL (25 mg/mL) S |
| Therapeutic Class | VEGF inhibitor; anti-angiogenic agent |
| ATC Code | L01XX44 |
| Manufacturing & Regulatory | |
| Manufacturer | Sanofi‑Aventis |
| Country | Germany/Mexico/India |
| GMP Compliance | WHO‑GMP |
| DMF/CEP | Biologic product (no conventional DMF) |
| COFEPRIS | 010.000.5995.00 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 Vials |
| Shelf Life | 24 Months |
| Storage | 2–8 °C; protect from light; do not freeze |
| Incoterms | FOB / CIF / DDP standard |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Upon Request |
| SDS | Upon Request |
| CTD Summary | Upon Request |
Description
Indications & Use: Intravitreal 2 mg injection for wet AMD, DME, DR, RVO, ROP; IV 100 mg/4 mL with FOLFIRI for metastatic colorectal cancer. Aflibercept is being researched for its potential to inhibit angiogenesis in VEGF-expressing breast cancers, particularly triple-negative breast cancer, through targeted delivery of anti-VEGF therapy.
